Category - Feature

Feature

Micromedic seeking diagnostic partners on multiple fronts

By Len Zehr With approvals in Europe and Israel for its CellDetect non-invasive test for recurrence of bladder cancer, Micromedic Technologies (TASE:MCTC) is seeking FDA approval for a pivotal trial expected to begin in...

October 25, 2016

Feature

Immunovaccine targets three clinical milestones

By Len Zehr Immunovaccine (OTCQX:IMMVF; TSX:IMV) expects to report three clinical milestones for its killer T cell activation vaccine platform, DepoVax, in ovarian and HPV cancers in the next 12 months. “Our DepoVax...

October 18, 2016

Feature

William Blair analyst discusses Hep B space

By Len Zehr As a partner and biotechnology analyst with William Blair & Co., Y. Katherine Xu was recognized in 2010 by the Financial Times/StarMine “World’s Top Analysts” listing, ranking No. 7 overall for stock...

October 11, 2016

Feature

Mesoblast developing multiple cell-based products

By Len Zehr Mesoblast (NASDAQ:MESO; ASX:MSB) has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of...

October 4, 2016

Feature

Knight Therapeutics “to get real” as it builds its commercial operations

By Len Zehr In the more than 30 months since its startup, Knight Therapeutics (TSX:GUD) has shown an uncanny knack for raising equity at increasing valuations, building a portfolio of some 20 innovative products for its...

September 20, 2016

Feature

Mateon taking VDAs in new direction against cancer

By Len Zehr Mateon Therapeutics (NASDAQ:MATN) is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal tumor blood vessels, which supply nutrients to cancer cells, with an initial clinical focus...

September 13, 2016

Feature

Lupus Foundation puzzled by negative reaction to Aurinia data

By Len Zehr As president and CEO of The Lupus Foundation of America (LFA), a role she has held for 15 years, Sandra Raymond is an outspoken advocate for the plight of lupus patients. She has worked with the board of...

September 6, 2016

Feature

BioSyent to target international markets

By Len Zehr BioSyent (OTC:BIOYF; TSX-V:RX) is actively building its international pharmaceutical sales and marketing business, adding products licensed and sold internationally to products already being shipped from...

August 30, 2016

Feature

Oramed hopes to start Phase 3 oral insulin trial next year

By Len Zehr After posting positive Phase 2b results with its oral insulin drug candidate, ORMD-0801 in Type 2 diabetes, Oramed Pharmaceuticals (NASDAQ:ORMP) hopes to meet with the FDA before the end of 2016 to discuss...

August 23, 2016

Feature

In conversation with Ben Haynor

By Len Zehr As a senior research analyst with Feltl & Co. for the past six years, Ben Haynor ranked second in the May 2013 Wall Street Journal Best on the Street publication in the Medical Equipment and Supplies...

August 16, 2016

Category - Feature

Subscribe